The approval of bemotrizinol could significantly benefit public health by improving sunscreen effectiveness and usability. Enhanced UVA protection may reduce risks of skin aging, pigmentation, and skin cancer, while the ingredient's photostability ensures consistent protection over time. Current U.S. sunscreens often fall short compared to international products, potentially leaving Americans at greater risk of UV-related skin damage. The limited availability of advanced sunscreen filters in the U.S. has also restricted consumer choice, which may discourage regular sunscreen use. By expanding the range of available options, bemotrizinol could make sun protection more accessible and appealing, particularly for individuals with diverse skin types and tones. However, the FDA's lengthy approval process has delayed access to such innovations, potentially impacting skin cancer prevention efforts.